GlycoMimetics, the company behind GlycoMimetics stock, changes ticker to CBIO

GlycoMimetics, the issuer behind GlycoMimetics stock, performed a 1-for-100 reverse split. Robinhood lists a 1:1 CUSIP change on September 30, 2026.

GlycoMimetics, the company behind GlycoMimetics stock, performed a 1-for-100 reverse split and changed its ticker to CBIO, according to Robinhood on September 30, 2026. The same entry records a 1:1 CUSIP change for the successor security.

GLYC gives way to CBIO

The corporate action changes the market identity attached to the former GLYC listing. One new share represents 100 previous shares, a ratio that materially alters the historical share count and makes older per-share figures difficult to compare directly with the current security.

Investing.com identifies the successor as Crescent Biopharma Inc, ticker CBIO, listed on Nasdaq, with ISIN KYG2545C1042. The page also states that the company was formerly known as GlycoMimetics, Inc., linking the former GLYC name to the current corporate identity.

The corporate identity has changed

The transition is more than a symbol adjustment. It combines a 1-for-100 reverse split with a new ticker and a CUSIP change, so investors reviewing historical GLYC filings need to distinguish legacy GlycoMimetics data from the successor company's current disclosures.

An analysis published by AInvest on September 10, 2026, says the reverse merger closed in June 2025 and that the reverse split left former GlycoMimetics shareholders with about 3 percent of the combined company. The same report places the next major proof-of-concept data point in the first quarter of 2027.

What the ticker change means

The practical takeaway is a break in continuity between the old GLYC quote and the current CBIO listing. The 1-for-100 ratio, the September 30, 2026 corporate-action date and the 1:1 CUSIP change are the key reference points for reconciling broker records and historical price charts.

GlycoMimetics stock status

• Company: GlycoMimetics, Inc.
• Ticker: GLYC, changed to CBIO
• Sector / Industry: Healthcare / Biotechnology